Search This Blog

Tuesday, June 9, 2026

TG Therapeutics positive topline Phase 1 data for subcutaneous BRIUMVI in myasthenia gravis

 

TG Therapeutics reports positive topline Phase 1 data for subcutaneous BRIUMVI in myasthenia gravis

  • Company initiates potentially registration-directed Phase 2 maintenance trial of subcutaneous BRIUMVI in myasthenia gravis.
  • Phase 2 maintenance study follows efgartigimod induction therapy in patients with myasthenia gravis.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)